Clinical trials
Multicenter Study clinical trials
Below are recruiting multicenter study clinical trials, each written for real people, not researchers. We’re tracking 405 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07808827RecruitingPhase 3
New targeted drug plus chemo for large b-cell lymphoma
This trial compares a new targeted medicine (JS203) combined with chemotherapy against a standard treatment (rituximab) with chemotherapy for people whose large B-cell lymphoma has returned or not responded. The goal is to see if the new combination works better and to offer a possible new option.
Beijing, Beijing MunicipalityAges 18–75 - NCT07769528Recruiting
Heart pump support for severe heart failure
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07769892Recruiting
Blood and stool test for digestive tract cancer screening
This study is testing a new way to screen for cancers of the digestive tract using a simple blood and stool test. It is for people who are already scheduled to have a digestive tract endoscopy, and it may help find cancers earlier without extra invasive procedures.
Zhaoqing, GuangdongAges 45–74 - NCT06341556RecruitingPhase 2
Study of zanubrutinib as maintenance therapy for mantle cell lymphoma
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07703033Recruiting
Heart Impact Study for Breast Cancer Radiotherapy
This study looks at how information about the heart may affect treatment decisions for people receiving radiation therapy for breast cancer. It aims to help reduce heart-related side effects from treatment.
CopenhagenAges 35 years+ - NCT07673640Recruiting
Ruxolitinib cream with steroids for active vitiligo on face
This trial tests a cream (ruxolitinib) combined with corticosteroid treatment for people with active, non-segmental vitiligo that affects the face. It aims to see how well this combination works in real-world settings.
Shenzhen, GuangdongAges 12 years+ - NCT07657052Enrolling by invitation
Long-term safety and effectiveness of XH-S003 for PNH
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
Tianjin, JinanAges 18 years+ - NCT07663331RecruitingPhase 4
Adalimumab for adults with non-infectious uveitis
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07650708RecruitingPhase 4
Eye Dryness After LASIK Surgery With a New Dry Eye Treatment
This study tests whether a new eye lubricant called Miebo, given before LASIK vision correction surgery, reduces dry eye symptoms afterward. If you have mild-to-moderate dry eyes and need LASIK, this trial may help you stay more comfortable during your recovery.
Bozeman, MontanaAges 18 years+ - NCT07636824RecruitingPhase 2
Chemotherapy plus radiation after bile duct cancer surgery
This study tests whether combining chemotherapy and radiation therapy after surgery improves outcomes for patients with bile duct or gallbladder cancer. It's designed for patients whose surgery showed signs the cancer might come back.
BeijingAges 18–80 - NCT07622836Recruiting
Chemotherapy plus QL1706 for high-risk triple-negative breast cancer
This study tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy after surgery can help patients with aggressive triple-negative breast cancer that has spread to lymph nodes. The goal is to see if this combination prevents cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT07589569RecruitingPhase 2
HRS-7058 for Advanced Pancreatic Cancer Treatment
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
Nanjing, JiangsuAges 18–75 - NCT06730607Recruiting
Predicting heart rhythm problems after myocarditis
This study uses heart MRI scans to predict who might develop dangerous heart rhythms after recovering from myocarditis. It aims to find better ways to monitor patients and prevent emergencies.
Rozzano, MilanAges 18 years+ - NCT07532915Recruiting
Two endoscopy methods to prevent stomach vein bleeding
This trial compares two endoscopic (camera-guided) procedures to prevent or treat bleeding from enlarged veins in the stomach. Both approaches aim to stop dangerous bleeding or prevent it from happening in high-risk patients.
Guangzhou, GuangdongAges 18–80 - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT07419997Recruiting
Observational study on clot-busting drugs beyond the usual window
This study looks at patients who received a clot-busting drug (intravenous thrombolysis) for their stroke 4.5 to 24 hours after symptoms started. It aims to see how well this works and what happens to them, using data that has already been collected.
BeijingAges 18 years+ - NCT06261801Recruiting
Acupuncture plus pregabalin for shingles pain on the face
This trial tests whether adding acupuncture (electroacupuncture) to the standard pain medicine pregabalin can better relieve facial shingles pain that started 1 to 3 months ago. It's for people with moderate pain who are willing to try both treatments together.
Hangzhou, ZhejiangAges 18–85 - NCT07371208RecruitingPhase 2
Sac-TMT plus immunotherapy before surgery for triple-negative breast cancer
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07358078Recruiting
Long-term study of ATTR-CM patients on vutrisiran or other approved therapies
This study observes people with ATTR-CM (a heart condition caused by a protein called transthyretin) who are starting treatment with vutrisiran or another approved therapy. It aims to understand how the disease progresses and how treatments work in real life.
Tucson, ArizonaAges 18 years+ - NCT07348575Enrolling by invitationPhase 3
Decitabine plus R-CHOP for EBV-positive DLBCL
This trial tests whether adding a drug called decitabine to the standard chemo-immunotherapy R-CHOP can help people with a specific type of lymphoma (DLBCL that is positive for EBV) who have not been treated before. The goal is to see if the combination works better than R-CHOP alone.
Nanchang, JiangxiAges 18–75 - NCT07343089Recruiting
Study of Lyme disease during anti-CD20 treatment in France
This study looks at people who got a serious form of Lyme disease while being treated with a type of biologic drug called an anti-CD20 (such as rituximab). The goal is to learn more about these cases and improve care. You may join if you had Lyme disease confirmed by a DNA test within two years of taking this medicine.
StrasbourgAges 1 year+ - NCT07328243Recruiting
New treatment for thyroid cancer that spread to neck lymph nodes
This study tests a minimally invasive treatment called irreversible electroporation for thyroid cancer that has come back or spread to lymph nodes in the neck. It may be an option for people who can't have another surgery or for whom radioactive iodine therapy hasn't worked.
Guangzhou, GuangdongAges 18 years+
Hear when a new Multicenter Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multicenter study?
- Yes. Clin2 currently lists 405 recruiting multicenter study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multicenter study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multicenter study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.